News and Media

Interim 12-week analysis from the ongoing Phase 2a trial of an investigational novel gene therapy product, URO-902 (plasmid human cDNA encoding maxi-K channel), receives International Continence Society (ICS) recognition for “Best in Category Prize: Overactive Bladder.” Analysis from the trial suggests that URO-902 may be an effective, safe, and well tolerated treatment option in women […]

Urovant Sciences, Inc. receives Fortune and Great Place to Work Best Workplaces in Biopharma (2022) recognition. Follows Urovant’s Best Place to Work recognition by the Orange County Business Journal for the second year in a row, along with becoming a Great Places to Work-Certified™ company earlier this year. The Best Workplaces in BioPharma award is […]

July 27, 2022 at 4:05 PM EDT First fiscal quarter 2022 total revenue of $116.5 million, including net product revenue of $41.4 million Net product revenue from U.S. sales of ORGOVYX® of $36.0 million in first fiscal quarter 2022, with sequential quarterly demand volume growth of 26% and cumulative patients estimated at 18,000 through June 2022 Net product revenue from U.S. sales of MYFEMBREE® of $4.0 million in […]

July 13, 2022 at 8:00am PST Survey of 71 Directors of Nursing (DONs) highlights a need for improved awareness, education, and management of urinary incontinence (UI) related to overactive bladder (OAB) in long-term care (LTC) settings, according to this peer-reviewed journal paper. Surveyed DONs reported an average of 62% of their residents had UI, with 81% of […]

July 7, 2022 at 8:07am PST  This is Urovant’s second year in a row to earn this recognition by Orange County Business Journal Urovant has also received a 2022 global Great Place to Work™ certification. The culmination of these two awards reflects the company’s people focused culture and underscores the opinion of employees, dedicated to improving […]

July 5, 2022 at 8:05am EST Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the European Economic Area, UK, and Switzerland. Urovant Sciences GmbH to receive compensation of up to USD $75 million in upfront payment, regulatory, and sales milestones as well as royalties […]

June 17, 2022 at 6:45 AM EDT BASEL, Switzerland and NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that results of the Phase 3 SPIRIT 1 and SPIRIT 2 studies of investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in over 1,200 women […]

June 2, 2022 at 6:50 AM EDT BASEL, Switzerland and NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg). The sNDA proposes updates to MYFEMBREE’s […]

The facilities are located in the center of Philadelphia’s thriving life sciences corridor Philadelphia, PA, May 17, 2022 – Spirovant Sciences, a gene therapy company developing treatments for inherited respiratory diseases, including cystic fibrosis (CF), announced today the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia. The new research facilities will allow […]

May 15, 2022 at 10:00 AM EDT New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA® (vibegron) 75 mg provided additional insight into the long-term durability of the product. These data were featured in podium presentations PD 38-11 and PD 38-12: In a subgroup analysis of adults, 65 years old or above […]

May 13, 2022 at 11:30 PM CDT Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the common symptoms of overactive bladder (OAB) compared to placebo. (Plenary Presentation PLLBA-03) In this prespecified 12-week analysis of a Phase 2a […]

May 10, 2022 at 6:55 AM EDT Fiscal year 2021 total revenue of $231.0 million, including net product revenues of $94.3 million; fourth fiscal quarter 2021 total revenues of $57.6 million, including net product revenue of $32.4 million European Commission approval of ORGOVYX® as the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe in April 2022 Announced exclusive […]

May 9, 2022 at 6:30 AM EDT Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to $90.5 million Myovant also eligible to receive tiered royalties from the high-teens to mid-twenties on net sales BASEL, Switzerland and HARROW, United Kingdom, May 09, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) and Accord Healthcare, […]

CARY, N.C., and BASEL, Switzerland – May 6, 2022 – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company is presenting results from a preclinical study comparing rodatristat ethyl as a monotherapy and in combination with the type A endothelin receptor antagonist, ambrisentan, in an animal […]

CARY, N.C., and BASEL, Switzerland – May 2, 2022 – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, announced today that the company made an oral presentation of preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome (BOS) at the International Society for Heart & Lung […]